Key result
Liposomal doxorubicin HCl yields considerable tumor regression in a cutaneous angiosarcoma case failing prior therapies.
Why the study?
Does liposomal doxorubicin HCL improve tumor regression in a patient with cutaneous angiosarcoma?
Case Report (n=1)
Does liposomal doxorubicin HCL improve tumor regression in a patient with cutaneous angiosarcoma?
Liposomal doxorubicin may offer an effective chemotherapy option for cutaneous angiosarcoma compared to conventional palliative therapies.
Answers are grounded in this paper and cite their sources.
May support use in refractory cutaneous angiosarcoma; hypothesis-generating and should not yet change practice.
The case of a 65 year old patient with a cutaneous angiosarcoma of the head and facial skin is reported. In contrast to preceding chemo-and radiation therapies which did not induce any tumor regression, our treatment with liposomal doxorubicin HCL (Doxil®) caused considerable tumor regression. This therapy had to be stopped because of accumulated toxic side effects after multiple chemotherapies. The therapy with liposomal doxorubicin is known to yield good results in the therapy of Aids-related Kaposi's sarcoma and is usually well tolerated. We assume that liposomal doxorubicin could be an effective chemotherapy compared to the conventional and in most cases only palliative therapies.
No takes yet. Share an insight, caveat, or question.
H.M. Ockenfels (1996) conducted a case report in Cutaneous angiosarcoma (n=1). Liposomal doxorubicin HCL (Doxil) vs. Preceding chemo- and radiation therapies was evaluated on Tumor regression. Treatment with liposomal doxorubicin HCL caused considerable tumor regression in a 65-year-old patient with cutaneous angiosarcoma, contrasting with prior therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: